Direxion Daily Semiconductor Bear 3X Shares vs State Street SPDR S&P Biotech ETF — how do they compare? Direxion Daily Semiconductor Bear 3X Shares trades at $45.54, while State Street SPDR S&P Biotech ETF trades at $154.37. Which is the better fit depends on your goals.
| SOXS | XBI | |
|---|---|---|
Sector | Leveraged / Inverse | Broad Market / Factor |
52-Week High | $1.61K | $164.28 |
52-Week Low | $32.50 | $85.16 |
Signals from Pluang's Aura AI — not financial advice
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, trades at $53.99, down 1.64% with a bearish moving average signal but bullish overall technical outlook. The ETF provides 3x leveraged inverse exposure to semiconductors, recently benefiting from sector volatility. A 1:10 stock split is scheduled for July 26, 2026, following a $0.04 dividend payment in June. Recent news highlights SOXS's surge during semiconductor sell-offs, with the ETF gaining attention as a tactical instrument amid AI-driven chip market fluctuations.
SOXS offers leveraged inverse exposure to semiconductor stocks, presenting high-risk, tactical opportunities during sector downturns. The bullish technical signal contrasts with overbought RSI readings, suggesting potential near-term volatility. Key risks include leverage decay, sector reversal momentum, and dependence on semiconductor market weakness. Investors should approach SOXS as a short-term hedging tool rather than a long-term holding due to its inverse structure and high volatility.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Trailing returns across standard periods
Latest headlines on both assets
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →